Filing Flows › Health Care › Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · Alnylam Pharmaceuticals (ALNY) Q3 2026 earnings results →

Q3 2026 Revenue up 17% year over year to $1.5B · 149¢ of every $1 of revenue kept as net profit · operating margin 23.7%

Alnylam Pharmaceuticals made $1.5B in Q3 2026 (+17% Y/Y): Net product revenues $1.3B, Total Rare $142M, ONPATTRO $19.6M. Operating margin 23.7%, net earnings $2.2B. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

Embed this chart on your site

Picture with a link (blogs, newsletters, forums)<a href="https://filing-flows.com/c/alny/"><img src="https://raw.githubusercontent.com/eurikamonica/filing-flows/media/og/alny-revenue-breakdown-sankey.jpg?v=07c0dd88f2" alt="Alnylam Pharmaceuticals Q3 2026 revenue breakdown: Sankey diagram of revenue (Net product revenues, Total Rare, ONPATTRO), costs, profit and cash flow" width="600" style="max-width:100%;height:auto"></a><br><small>Alnylam Pharmaceuticals Q3 2026 revenue breakdown — <a href="https://filing-flows.com/c/alny/">Filing Flows</a></small>Interactive chart<iframe src="https://filing-flows.com/c/alny/embed/" width="100%" height="460" style="border:0;max-width:900px" loading="lazy" title="Alnylam Pharmaceuticals Q3 2026 revenue breakdown: Sankey diagram of revenue (Net product revenues, Total Rare, ONPATTRO), costs, profit and cash flow"></iframe><br><small>Alnylam Pharmaceuticals Q3 2026 revenue breakdown — <a href="https://filing-flows.com/c/alny/">Filing Flows</a></small>

Free to use with the credit line. Click a box to select the code.

What changed this quarter

Quarterly history

Charts

Interactive views

The same charts as the app — open one to draw it.

Customers and suppliers named in filings

Sells to

• NVS — 23% of its revenue · Stated in 10-K (customer table) · source
• REGN — 11% of its revenue · Stated in 10-K (customer table) · source
• ABUS · Stated in 10-K (named, share not stated) · source

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, that function upstream of conventional medicines by potently silencing messenger RNA, or mRNA, that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. We believe this is a revolutionary approach with the potential to transform the care of patients across a broad range of disease areas and indications.

In its own words, from its 10-K, filed Feb 12, 2026.

Alnylam Pharmaceuticals against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +17% against the peers' median +10%. Operating margin: 23.7% against the peers' median 23.7%.

Source: Alnylam Pharmaceuticals 10-Q on SEC EDGAR · CIK 1178670 · Pharmaceutical Preparations

中文版：Alnylam Pharmaceuticals（ALNY）财报

Español · Français